Brian Abrahams

“You mentioned in milestones the potential for inclusion of Selenexer in the compendia in the back half of this year. That seems pretty rapid if the NCCN meeting is happening just this week.”

“First, can you characterize your payer conversations and just the latest views on the potential pricing benchmarks for Rizzetta calendar and receptivity to potential premium pricing, just given all of its profile advantages?”

“On the expense side, it looks like you've lowered your OPEX guidance for this year. And I think you've talked in the past about the 800-ish range being a good steady state to think about.”

“Maybe first on Nevenibart, just with the enrollment completion and upsizing in that study, just wondering if I guess the upsizing was based on just like higher than expected interest or on any kind of observations on dropouts, the types of patients you're seeing there and sort of any implications for powering.”

“So, it sounds like the earlier Your line in EtoCell study enrolls really quickly and filing could happen as early as next year.”